Nov 29, 2018 · Results produced in our study suggest that elotuzumab is highly effective when used in pts with RRMM and NDMM. Combination regimens for elo produces an ORR ranging from 79-83% with elo + lena+ dexa, proving that the best …

The triplet combination elotuzumab, lenalidomide and dexamethasone (Elo-Rd) led to an ORR of 84%, including 14% of stringent complete response and 42% of VGPR. The 10 mg/kg cohort was associated with a better efficacy with a median PFS of 32 …

Nov 7, 2018 · Here, we report the results from ELOQUENT-3, a randomized trial in which we assessed the efficacy and safety of the monoclonal antibody elotuzumab plus pomalidomide and dexamethasone as compared...

Nov 29, 2018 · Elo (10 mg/kg IV) was given weekly in Cycles 1-2, and at 20 mg/kg IV every 4 wk thereafter. Laboratory assessments of efficacy were performed every 4 wk and evaluated using modified International Myeloma Working Group criteria.

Jan 7, 2025 · Elo provides faster relief from the symptoms of hay fever, allergic rhinitis such as sneezing, nasal discharge, itching, ocular itching and burning, nasal and ocular sign and symptoms are relieved rapidly after oral administration. Elo is also effective in …

May 29, 2024 · We report final results of a phase 2 trial evaluating the efficacy and safety of adding elotuzumab (ELO) to LEN as maintenance therapy post- AuSCT. Methods: On 28-day cycles, patients received ELO 10mg/kg iv weekly for cycles 1-2.Between 4/15/2015-1/27/2016, 27 pts received ELO 10mg/kg q2 weeks for cycles 3-6 and 20mg/kg monthly for cycles 7+.

Sep 24, 2024 · Elo 10 mg Tablet provides faster relief from the symptoms of hay fever, allergic rhinitis such as sneezing, nasal discharge, itching, ocular itching and burning, nasal and ocular sign and symptoms are relieved rapidly after oral administration.

Nov 16, 2012 · Elotuzumab (Elo) is a humanized monoclonal IgG1 antibody targeting CS1, a cell surface glycoprotein highly expressed on >95% of MM cells, with lower expression on natural killer (NK) cells and little to no expression on normal tissues.

Elo 10mg Orodispersible Tablet is indicated for the symptomatic treatment of allergic rhinitis (AR) and chronic idiopathic urticaria (CIU). Temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: Adults and children over 12 years of age. 10 mg once daily (one orodispersible tablet once daily).